Anika Therapeutics (Anika Therapeutics) Cash And Cash Equivalents : $72.9 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics Cash And Cash Equivalents?

Anika Therapeutics's quarterly cash and cash equivalents increased from Jun. 2023 ($65.07 Mil) to Sep. 2023 ($70.65 Mil) and increased from Sep. 2023 ($70.65 Mil) to Dec. 2023 ($72.87 Mil).

Anika Therapeutics's annual cash and cash equivalents declined from Dec. 2021 ($94.39 Mil) to Dec. 2022 ($86.33 Mil) and declined from Dec. 2022 ($86.33 Mil) to Dec. 2023 ($72.87 Mil).

Anika Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Anika Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Cash And Cash Equivalents Chart

Anika Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

157.46

95.82

94.39

86.33

72.87

Anika Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															86.33	79.74	65.07	70.65	72.87

Anika Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Anika Therapeutics (NAS:ANIK) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Anika Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Anika Therapeutics (Anika Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

AKP:Germany

Address

32 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.anika.com

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Executives

Anne Nunes	officer: SVP, Chief Operations Officer	32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti	director	600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran	officer: EVP, General Counsel, Corp Sec	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz	officer: EVP, CFO, Treasurer	C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land	director
Stephen Richard	director	C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop	officer: EVP Business Development	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung	officer: CFO	ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen	director	32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower	director	32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson	director	1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling	officer: President	501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767